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Abstract
Background: The increasing prevalence and associated cost of treating chronic obstructive pulmonary disease
(COPD) is unsustainable, and focus is needed on self-management and prevention of hospital admissions.
Telehealth monitoring of patients’ vital signs allows clinicians to prioritise their workload and enables patients to
take more responsibility for their health. This paper reports the results of a pilot randomised controlled trial (RCT) of
Telehealth-supported care within a community-based COPD supported-discharge service.
Methods: A two-arm pragmatic pilot RCT was conducted comparing the standard service with a
Telehealth-supported service and assessed the potential for progressing into a full RCT. The co-primary outcome
measures were the proportion of COPD patients readmitted to hospital and changes in patients’ self-reported
quality of life. The objectives were to assess the suitability of the methodology, produce a sample size calculation
for a full RCT, and to give an indication of cost-effectiveness for both pathways.
Results: Sixty three participants were recruited (n = 31 Standard; n = 32 Telehealth); 15 participants were excluded
from analysis due to inadequate data completion or withdrawal from the Telehealth arm. Recruitment was slow
with significant gaps in data collection, due predominantly to an unanticipated 60% reduction of staff capacity
within the clinical team. The sample size calculation was guided by estimates of clinically important effects and
COPD readmission rates derived from the literature. Descriptive analyses showed that the standard service group
had a lower proportion of patients with hospital readmissions and a greater increase in self-reported quality of life
compared to the Telehealth-supported group. Telehealth was cost-effective only if hospital admissions data were
excluded.
Conclusions: Slow recruitment rates and service reconfigurations prevented progression to a full RCT. Although
there are advantages to conducting an RCT with data collection conducted by a frontline clinical team, in this case,
challenges arose when resources within the team were reduced by external events. Gaps in data collection were
resolved by recruiting a research nurse. This study reinforces previous findings regarding the difficulty of undertaking
evaluation of complex interventions, and provides recommendations for the introduction and evaluation of complex
interventions within clinical settings, such as prioritisation of research within the clinical remit.
Trial registration: Current Controlled Trials ISRCTN68856013, registered Nov 2010.
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Background
Given the forecast increasing prevalence of chronic ob-
structive pulmonary disease (COPD), current models of
care provision are unsustainable and must adapt to em-
brace prevention and self-management [1]. This poten-
tially requires individuals diagnosed with COPD to be
supported to manage the disease at home, thereby avoid-
ing hospital admission and reducing healthcare costs [2].
COPD is characterised by progressive worsening of
lung capacity. Patients with advanced COPD typically
experience impaired physical, emotional, and social func-
tioning which results in poor quality of life [3]. In the UK,
COPD is the fifth largest cause of mortality and the sec-
ond largest cause of emergency admissions to hospital [4].
COPD costs the National Health Service (NHS) over £800
million per annum [5].
Remote monitoring of patients’ physiology and symp-
toms using Telehealth is considered to be highly appro-
priate for people with COPD, a condition which is
associated with frequent hospital admissions and high
levels of disability and depression [6,7]. It involves the
remote exchange of patient data (e.g., vital signs) be-
tween a patient and clinician which can be used to iden-
tify potential deterioration, prevent avoidable hospital
admissions, and help improve an individual’s quality of
life [8]. Telehealth also has the potential to help patients
improve their ability to self-manage their condition, e.g.,
through patient education [7].
A recent Cochrane review [7] demonstrated the poten-
tial for Telehealth in reducing hospital admissions and
increasing quality of life; however, in the identified stud-
ies, Telehealth was usually delivered as part of a more
complex package of care and, thus, it was difficult to
separate the effect of the technology from other aspects
of the service. The recently reported results of a large
scale UK trial of Telehealth also demonstrated that use
of this technology within services has the potential to re-
duce mortality and emergency admission rates [9]; how-
ever, the results were not definitive in that the same
study failed to demonstrate cost-effectiveness. Neverthe-
less, implementation of Telehealth remains a policy pri-
ority in the UK [10] and internationally, for example,
through the Veterans’ Association in the US [11] and
across Canada [12]. Despite the cited benefits of Tele-
health [13], research has illustrated that patients and
front line clinicians may not be receptive to the inter-
vention, with the extent of staff training and support
that is necessary to embed such technology into routine
practice being emphasised [14].
This paper reports results from the pilot stage of a prag-
matic randomised controlled trial (RCT) of a Telehealth-
supported service and a standard service pathway
provided through one hospital discharge service for people
with COPD within one primary care trust (PCT) in the
UK. Findings are reported in accordance with the Consoli-
dated Standards of Reporting Trials (CONSORT) check-
list for clinical trials [15].
Study context
In May 2009, a PCT in the North of England introduced
a dedicated discharge service for individuals with early
stage COPD as defined locallya. It had been identified by
the PCT that approximately 1,200 patients with COPD
were being discharged from local acute in-patient ser-
vices annually. A standard (non-Telehealth-supported)
service was established to assist patients to manage their
illness more effectively following hospital discharge, with
the aim of decreasing readmission rates. Two COPD
specialist nurses, one specialist physiotherapist, and one
community matron were employed full time within the
service. The COPD supported discharge service received
referrals from the local NHS Acute Care Trust via two
routes: i) specialist COPD nurses based on respiratory
wards who were able to refer patients directly and ii) a
telephone referral route allowed any relevant staff mem-
ber within the hospital to refer a patient with a diagnosis
of COPD, even if COPD was not the primary cause of
their admission (see below for full referral criteria).
Criteria for referral to the supported discharge service
! SpO2 > 90% on air or pO2 > 7 kPa/pH 7.35–7.45
! Respiratory rate <25
! Temperature <37.8°C
! Systolic blood pressure 90–180 mm/Hg
! Pulse 50–100 BPM
! Orientated and alert/able to give consent
! Safe discharge environment
! Between 1 and 3 previous admissions (including the
current admission) in the previous 12 months from
the current date of discharge where COPD is the
primary or secondary documented reason for
hospitalisation
The service involved six home visits over the 8-week
time frame, resulting in a conservative estimate of
8 hours and 25 minutes of time spent with each patient
(including clinical administration time and cancelled ap-
pointments). It was recognised by the PCT that a service
which was delivered entirely face-to-face was unsustain-
able in the long term, particularly given the numbers of
patients presenting to acute care with COPD and in the
context of an ageing population and static NHS budgets.
A subsequent decision was taken by the PCT to intro-
duce Telehealth within the discharge service. The se-
lected Telehealth system (Doc@Home®) enables the
patient to undertake daily vital signs monitoring. If mon-
itored signs and symptoms fall outside anticipated
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parameters for the individual, or if the user fails to
undertake monitoring activity, clinician alerts are gener-
ated so that appropriate action can be taken.
Table 1 provides an overview of the standard service
and Telehealth-supported service. It was estimated that
reduction of the number of home visits and inclusion of
remote monitoring of patients’ vital signs could reduce
the average time spent on each patient to 5 hours 30 mi-
nutes, thus better utilising staff resources and reducing
costs. Telehealth equipment was to be provided to pa-
tients for 8 weeks, in accord with the overall service
offer. Agreements were established between the PCT,
Local Authority, and equipment provider for the instal-
lation, delivery, alert management, and de-installation of
the equipment. Both the standard service and the
Telehealth-supported service are free at the point of de-
livery for its users.
The research programme
The overall research questions (agreed with the PCT ser-
vice commissioners and managers) were as follows:
! Does a Telehealth-supported discharge service
decrease hospitalisations compared to the standard
service?
! Does a Telehealth-supported discharge service result
in improved quality of life for people with COPD
compared to the standard service and does this
change over time?
! Does a Telehealth-supported discharge service
reduce use of NHS resources compared to the
standard service?
Study design was informed by the Medical Research
Council guidance for evaluating complex interventions
[16]. It involved a feasibility study (reported elsewhere)
which investigates the practicalities of undertaking the
research, e.g., flow of referrals into the discharge service
and clinician/patient engagement levels. The feasibility
study was followed by a pilot randomised controlled trial
(RCT) to finalise study methods. The intention was to
then continue to a full RCT, as described in the pub-
lished protocol [17].
The specific objectives of the pilot randomised con-
trolled trial were to i) test the trial methodology, namely
recruitment, randomisation, intervention implementa-
tion, and outcome measurements; ii) estimate the sam-
ple size required for a full trial, through analysis of data
on patient contact with other services, including hospital
admissions; and iii) conduct a preliminary evaluation of
the cost-effectiveness of the Telehealth intervention
through analysis of healthcare usage, patient contact data,
and quality of life data.
Methods
The study reported in this paper involved a pragmatic
two-arm pilot RCT informed by the findings from a prior
feasibility study. The pilot RCT followed an ‘internal/ex-
ternal’ design [18] so that, if the chosen methods were
consistently and rigorously applied, the pilot data might
be incorporated into a full trial.
The pilot trial was conducted over 14 months. Through-
out the data collection period close contact was main-
tained with all stakeholders via monthly project steering
meetings. Records were maintained of emergent issues
and identified solutions. The feasibility study identified
that a target sample size of n = 60 participants, recruited
over a 3 month period, would be acceptable for the pilot
RCT given the number of referrals into the service and an
estimated acceptance rate of 32% [17]. As shown in
Table 2, potential candidates were approached by a COPD
discharge team clinician during the first post-discharge
home visit and were provided with study information if
they expressed interest in participating. During the second
visit 48 hours later, further information was provided and
written consent then obtained from those who wished to
participate. Random allocation to the two arms of the trial
was generated through a web-based programme, accessed
by the administrator for the COPD service, who generated
the allocation online and informed the clinician immedi-
ately following receipt of consent. Participants received
their allocated treatment pathway for 8 weeks, with a
Table 1 Summary of standard and Telehealth-supported services
Timeline Standard COPD service Telehealth-supported COPD service
1 day – First home visit after hospital discharge Home visit Home visit
3 days Home visit Home visit
5 days Home visit Home visit
Telehealth equipment installed
2 weeks Home visit Remote review of Telehealth parameters throughout 8 weeks
6 weeks Home visit Remote review of Telehealth parameters throughout 8 weeks
8 weeks Discharge home visit Discharge home visit
Telehealth equipment removed
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subsequent 6-month follow-up period after being dis-
charged from the service (total trial time frame of
8 months). It was not possible to blind the involved parties
due to the complex nature of the intervention and the
study design.
The COPD discharge team were responsible for col-
lecting completed self-report data during the 8-week
intervention. Although it was recognised that this ap-
proach would need to be carefully monitored, clini-
cians were involved in data collection for a number of
reasons:
! The nursing team were concerned that patients may
become stressed if receiving multiple visitors (e.g.,
COPD nurse plus research nurse) whilst recovering
from severe illness;
! The commissioning team wished to generate robust
evidence but had limited funds with which to do
this;
! One of the remits of the funding body
(Collaboration for Leadership in Applied Health and
Research Care for South Yorkshire) was to involve
multiple partners in research, including frontline
clinical staff, in order to bridge the gap between
research and implementation in healthcare [19].
The clinical team underwent Good Clinical Practice
(GCP) training and were carefully instructed in the re-
quirements of the protocol.
Inclusion/exclusion criteria
The recruitment inclusion/exclusion criteria were as
follows:
Inclusion criteria
! Between one and three previous admissions
(including the current admission) in the previous
12 months from the date of discharge with COPD
as the primary or secondary documented reason for
hospitalisation;
! Referred to the COPD discharge service;
! Willing to consider using Telehealth as part of the
discharge plan;
Table 2 Care pathways and integrated research activity
Timeline Standard COPD service Telehealth-supported COPD service
Intervention 1 day – First home visit after hospital
discharge (baseline time 0)
Home visit (Trial info pack) Home visit (Trial info pack)
3 days Home visit: Home visit:
Consent Consent
Baseline SGRQ (paper) Baseline SGRQ (paper)
Baseline EQ-5D (paper) Letter to inform GP of trial
GP record diaries (paper)
Letter to inform GP of trial
5 days Home visit Telehealth equipment installed
Baseline EQ-5D (device)
GP visit data (device)
2 weeks Home visit Remote review of Telehealth parameters
throughout 8-week intervention
5 weeks 5-week EQ-5D (paper) 5-week EQ-5D (on device)
6 weeks Home visit
8 weeks Discharge home visit: Discharge home visit:
8-week SGRQ (paper) 8-week SGRQ (paper)
Given materials for 6-month SGRQ Given materials for 6-month SGRQ
Given monthly EQ-5D and GP visit diaries Given monthly EQ-5D and GP visit diaries
Telehealth equipment removed
Follow-up 8 months (6 months after discharged
from service)
Measurement of outcomes (postal return): Measurement of outcomes (postal return):
Completion of 6-month SGRQ Completion of 6-month SGRQ
Completion of monthly EQ-5D Completion of monthly EQ-5D
Completion of monthly GP record visit diaries Completion of monthly GP record visit diaries
EQ-5D, EuroQol 5 Dimensions; GP, General practitioner; SGRQ, St. George’s Respiratory Questionnaire.
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! Able to communicate in English and read English (a
requirement of the technology);
! Have a telephone landline in the home (a
requirement of the technology).
Exclusion criteria
! Cognitive impairment to the extent that it impedes
ability to participate;
! Other significant impairment(s) which restrict ability
to participate;
! Existence of co-morbidities which require ongoing
intervention from other community services;
! More than three hospital admissions for COPD
within the prior 12 months;
! General practitioner (GP) identifies that person is
unsuitable to participate (e.g., due to a mental health
condition which could affect outcome
measurements).
Data collection
Table 2 provides more detail on trial pathways and data
collection time points. The main planned sources of data
collection were:
1. Researcher-collected data: demographic information
(age and sex) were collected by the research team
from routine referral records. Extracts from the
Secondary Uses Service (SUS (http://www.hscic.gov.
uk/sus)) database, which provides data on hospital
readmissions, were provided by the (blinded) PCT
statistical team to the research team for each
participant for the 8 months that they participated
in the trial.
2. Clinician-collected data: the St. George’s Respiratory
Questionnaire (SGRQ), a validated self-measure of
respiratory disease-related quality of life [20], was
completed by the participant at baseline and 8 weeks,
and was to be overseen and collected by the visiting
clinician. SGRQ was also completed at 8 months
(6 months post-intervention) and returned to the
research team via post. This was supplemented by
members of the clinical team calling participants to
remind them to complete and send their 8-month
SGRQs;
3. Device-collected data: a self-report patient-completed
diary to record GP visits was recorded on paper by
participants receiving the standard service and was
configured to be completed on the device by those
receiving Telehealth, during the 8-week intervention.
During the 6-month follow-up, participants in both
trial arms were asked to complete monthly paper
diaries recording their GP visits. The EuroQol 5
Dimensions questionnaire (EQ-5D-3 L), a widely used
measure of health outcomes standardised in a wide
variety of conditions [21], was embedded into the GP
diaries for those allocated to the Standard service
and into the device for participants with the
Telehealth-supported service.
Outcome measures
The two co-primary outcome measures were:
1. The proportion of participants re-admitted to
hospital with COPD during the 8-week intervention
and 6-month follow-up, determined using SUS data
on hospital readmissions; and
2. Change in self-reported health-related quality of life
at baseline, 8 weeks, and 6-month follow-up through
application of the SGRQ [20].
The secondary outcome measures were:
1. The proportion of patients requiring unscheduled
healthcare support for the 8 week intervention
period and 6-month follow-up, determined through
analysis of SUS data and patient-completed diaries
of GP visits; and
2. Cost-effectiveness through quality adjusted life years
(QALYs) estimated from analysis of EQ-5D-3 L [21]
data, GP visit data, SUS data, and the COPD
discharge team’s patient contact records.
Analysis – primary outcome measures
Analysis was conducted on an intention-to-treat basis.
For the primary outcome measures, descriptive statistics
are presented. No inferential statistical analyses were
performed as the main objective of the study was to as-
sess the trial methodology.
Analysis – cost-effectiveness and cost utility
Data on hospital admissions and unscheduled healthcare
support, EQ-5D scores, and COPD team patient contact
records were to be accessed and analysed to provide an
indication of the cost-effectiveness of each care pathway.
A cost-utility analysis was carried out based on the esti-
mated costs of Telehealth equipment, installation and
de-installation of units, telemonitoring, and clinician
costs. The cost of a day of COPD-related hospital admis-
sion and other secondary care services, including acci-
dent and emergency (A&E) visits, were extracted from
the National Reference Costs Publication [22].
Ethics
All necessary NHS ethical and governance approvals
were obtained from the South Yorkshire Research Ethics
Committee (reference 10/H130/48) and from the rele-
vant PCT.
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Results
Throughout the trial, recruitment rate and quality of
data collection were significantly impacted by an un-
anticipated reduction in clinical staff capacity. These fac-
tors precluded progression to a full RCT in this setting.
The findings in relation to the three objectives of the
pilot RCT are outlined below.
Objective one: trial methodology
Recruitment
The CONSORT [15] flow chart for the pilot trial is shown
in Figure 1. Recruitment and intervention delivery took
place from November 2010 to December 2011, with
follow-up for 6-month post-intervention data capture
continuing to June 2012. Although the recruitment target
of n = 60 was achieved, this was attributed to the pilot
RCT time frame being extended from 3 to 14 months due
to slow recruitment to the study. During the trial time
frame, 450 patients were referred to the COPD discharge
service, of which 270 (60%) met the inclusion criteria. Of
these, 132 could not be considered for inclusion in the
study due to reasons other than declining participation, as
summarised in Table 3. Some of the most common rea-
sons were lack of clinician resources due to staff attrition
that resulted in a long waiting list for admission to the ser-
vice (thereby breaching the care and research protocol),
immediate hospital readmission, and patient holidays/holi-
day periods. Of the remaining patients, 75 declined to par-
ticipate and 63 (14%) agreed to enter the study and were
randomised. Trial acceptance rate was 45.7% (out of 138
patients who were eligible and were not excluded for other
reasons); 31 participants were randomised to the standard
service and 32 participants were randomised to receive
the Telehealth-supported service. The clinicians reported
that refusal to participate was most often due to the per-
son feeling too unwell.
Of the 63 randomised participants, data for 10 (15.9%)
were excluded from analysis as data completion was
Figure 1 CONSORT flow chart.
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inadequate. A further 5 participants randomised to the
Telehealth-supported service were lost to follow-up
(Table 4). In three instances, this was due to unexpected
problems with technology connectivity despite the exist-
ence of a protocol to screen out such problems. One
participant in each group died prior to completing the
6-month follow-up.
Protocol adherence and success of data collection strategy
Table 5 summarises the completeness of data collection
at each time point and provides an indication of extent
of adherence to the research protocol. A total of 83.3%
of participants completed the intervention within the 8-
week service delivery time frame.
After 6 months of data collection an audit was con-
ducted to determine adherence to data collection proce-
dures. Significant gaps were identified which resulted in
the initiation of additional procedures. The most signifi-
cant change was the introduction of a research nurse in
month 10 to take consent and collect trial-related data,
thereby relieving the clinical team of this responsibility.
Protocol adherence during the 8-week intervention in-
creased to 100% after the research nurse was involved.
As demonstrated in Table 5, there were many instances
of missing or invalid SGRQ data, with 56.6%, 54.2%, and
28.3% valid completion rates for each respective time
point (when excluding drop-outs and missing consent).
Only 43.8% of participants had a valid SGRQ score for
both baseline and 8-week time points, and this figure re-
duced to just 8.7% for all three time points. The SGRQ
is designed to be completed by the participant overseen by
a researcher or healthcare professional. Although this was
agreed in the protocol, clinicians tended to leave the SGRQ
with participants to complete in their own time. Clinician
feedback during the pilot was that they did not feel com-
fortable overseeing SGRQ completion as they were wary of
biasing participants’ responses when asked for advice.
The completion rate for the standard service 8-week
self-report diaries (which included the EQ-5D) was simi-
larly challenged. The standard service group EQ-5D
completion rate at baseline was 72.0% with a 5 week
completion rate of 44.0%, which did not allow compari-
son with EQ-5D data from the Telehealth-supported
group (embedded within Doc@Home). The self-report
diaries for the standard service group were completed in
44.0% of cases. The postal return of monthly diaries in
the 6-month follow-up (which were given to both
groups) did not yield meaningful data (12.5% returned).
Objective two: healthcare usage and sample size calculation
Baseline characteristics
Table 6 shows age and sex distribution for the 53 consented
participants. The Telehealth-supported group contained a
greater proportion of males and had a slightly higher mean
age. Lack of comparability between the two trial arms was
a likely consequence of the small sample size.
Healthcare service usage data
Data on the frequency and length (bed days) of hospital
admissions, frequency of A&E visits (which did not lead
to hospital admission), and frequency and type of
community healthcare service contacts (other than the
COPD discharge service) were extracted for all partici-
pants (who completed the 8 week intervention) for the
duration of the intervention and 6-month follow-up. Re-
sults summarised in Table 7 show that participants re-
ceiving the standard service had a lower readmission
rate, fewer hospital admissions, and fewer inpatient bed
days than those receiving the Telehealth-supported ser-
vice. Frequency of community healthcare service contact
was similar between the two groups. It was not possible
to infer the number of GP visits from the available data.
Sample size calculation
It was not possible to use the pilot RCT data to generate
a sample size calculation due to incomplete data collec-
tion. Therefore, the calculation was conducted using es-
timates of readmission rates, clinically meaningful effect
sizes based on the literature, and clinical expertise. A 10
to 20% relative reduction in hospital readmission rate
was deemed to be clinically meaningful. Table 8 shows
Table 3 Reasons for exclusion from trial
Reasons (n = 132) Number
(% of eligible patients)
Backlog on telephone referral waiting list 69 (25.6%)
Not seen within adequate trial time frame 15 (5.6%)
Readmitted to hospital straightaway 11 (4.1%)
Discharged over Christmas holiday period 10 (3.7%)
Disruptions to care pathway schedule 6 (2.2%)
Unable to contact 5 (1.9%)
Patient does not believe they have COPD 4 (1.5%)
Care home resident 3 (1.1%)
Unknown clinical reason 3 (1.1%)
Going on holiday 2
Discharged elsewhere 2
Leaving area 1
Offered trial previously 1
Table 4 Reasons for discontinuing Telehealth intervention
Reason Number
No landline 2 (0.4%)
Unable to install 1 (0.2%)
Refused unit at installation stage 1 (0.2%)
Found unit difficult to use 1 (0.2%)
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the sample sizes required to detect reductions in this
range, given 90% power to detect significant differences at
a P value of 0.05. If we take an intermediate value, with a
15% relative reduction in hospital admissions from 34% to
29%, 1,517 patients per arm (n = 3,034 total) would be re-
quired for a full RCT.
Objective three: quality of life and preliminary evaluation
of cost-effectiveness
SGRQ data analysis shows that both groups reported an in-
crease in disease-related quality of life (decrease in SGRQ
score) between baseline and 8 weeks (Table 9). However,
this increase was larger in the standard service group.
Table 5 Data completion for research outcomes
Standard Telehealth Total
Total randomised 31 (100%) 32 (100%) 63 (100%)
Consent
Valid consent 25 (80.6%) 28 (87.5%) 53 (84.1%)
Missing consent 6 (19.4%) 4 (12.5%) 10 (15.9%)
Dropped out
Prior to 8-week completion 0 (0.0%) 5 (15.6%) 5 (7.9%)
Prior to 8-month completion 1 (3.2%) 1 (3.1%) 2 (3.2%)
Intervention length
8 weeks 20 (64.5%) 20 (62.5%) 40 (63.5%)
Less than 8 weeks 0 (0.0%) 0 (0.0%) 0 (0.0%)
More than 8 weeks 5 (16.1%) 3 (9.4%) 8 (12.7%)
Baseline SGRQ
Valid 16 (51.6%) 14 (43.8%)* 30 (47.6%)
Invalid** 5 (16.1%) 3 (9.4%) 8 (12.7%)
Missing 4 (13.0%) 7 (21.9%) 11 (17.5%)
8-week SGRQ
Valid 11 (35.5%) 15 (46.9%) 26 (41.3%)
Invalid 2 (6.5%) 1 (3.1%) 3 (4.8%)
Missing 12 (38.7%) 7 (21.9%) 19 (30.2%)
6-month SGRQ
Valid 8 (25.8%) 5 (15.6%) 13 (20.6%)
Invalid 1 (3.2%) 1 (3.1%) 2 (3.2%)
Missing 5 (16.1%) 5 (15.6%) 10 (15.9%)
Had not reached time point by Jan12 10 (32.3%) 11 (34.4%) 21 (33.3%)
Participants with valid baseline & 8-week SGRQ data 9 (29.0%) 12 (37.5%) 21 (33.3%)
Participants with valid baseline, 8-week & 6-month SGRQ data 2 (6.5%) 2 (6.3%) 4 (6.3%)
*One participant who dropped out completed the baseline SGRQ; **Not enough completed questions to generate a valid score.
SGRQ, St. George’s Respiratory Questionnaire.
Table 6 Baseline demographic information
Demographic Standard Telehealth Total
Sex
Male, n (%) 7 (28.0%) 12 (42.9%) 19 (35.8%)
Female, n (%) 18 (72.0%) 16 (57.1%) 34 (64.2%)
Age (years)
Mean (SD) 65.88 (9.39) 67.22 (11.60) 66.59 (10.54)
Median (IQR) 68.00 (58.85–72.85) 70.80 (60.93–73.73) 69.60 (59.80–73.40)
Minimum 41.2 44.2 41.2
Maximum 78.4 90.9 90.9
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Due to gaps in data collection the analysis method was
adjusted so that EQ-5D scores were calculated from par-
ticipants’ SGRQ scores using a mapping formula pro-
duced in a previous study in patients with COPD [23].
This estimates EQ-5D score as a function of SGRQ total
score and sex. Quality adjusted life years (QALYs) were
calculated from the EQ-5D scores using the trapezium
rule. Missing data were imputed using the last
observation carried forward method. Costs and QALYs
were calculated for each group, and then used to plot
data on the cost-effectiveness plane and to produce asso-
ciated cost-effectiveness acceptability curves. A value of
£20,000 per QALY was used to determine the probability
that the intervention is cost-effective under current
funding conditions.
The primary analysis was based on all NHS costs and
was performed using estimates of unit costs and esti-
mates of resource use. There was a higher mean total
cost in the Telehealth-supported group (£1,750 vs. £580
for the standard service). Comparison with the mean
cost difference showed an incremental cost per QALY
gained of £68,811 (Table 10).
A secondary sensitivity analysis was carried out based
on just the costs relating to community care, i.e., Tele-
health and nursing contacts. The rationale for this was
that hospitalisations had a disproportionate effect on the
results, and being so rare in a pilot study, their mean ef-
fect was possibly largely due to chance.
The results of the secondary analysis, using only the
costs of community care, showed that there is a 71.4%
chance that the Telehealth-supported services are cost-
effective given the willingness to pay of £2,041 per
QALY gained (Table 11).
To summarise, when considering community care
costs only, and estimated equipment costs of £455 over
5 years with a fairly low utilisation rate (three users per
year), the Telehealth intervention is perceived to be
cost-effective. However, when hospital admissions data
are included in the analysis then the Telehealth interven-
tion is not deemed to be cost-effective.
Discussion
In this paper we describe a pilot randomised controlled
trial of a Telehealth intervention for COPD. The results
showed that it would not be feasible to continue the
pilot trial to a full RCT. In conducting this research we
have identified issues of critical importance for any sub-
sequent study of this complex intervention, including
the involvement of clinicians in recruitment and in the
research process. The service commissioners’ expect-
ation was that Telehealth-supported services might be
clinically and cost-effective for people receiving time-
limited support following hospital discharge. Although
the pilot trial has not been able to give a robust indica-
tion of clinical or cost benefit due to its small sample
size and incomplete data collection, it has achieved its
objective of demonstrating the practicalities of answering
these questions with a full scale RCT in this particular
setting.
Compared to studies recruiting participants at mul-
tiple sites and working with several clinical teams, it
could be presumed that working with one clinical team
Table 7 Healthcare service use by participants
Standard Telehealth Total
Sample size 25 23 48
Proportion with hospital admissions
Number 4 8 12
Percentage 16.0% 34.8% 25.0%
Number of hospital admissions
Total 7 16 23
Mean 0.28 0.70 0.48
Maximum 3 5 5
Total number of hospital days
Total 21 129 150
Mean 0.84 5.61 3.13
Maximum 14 43 43
Proportion with A&E visits
Number 4 1 5
Percentage 16.0% 4.3% 10.4%
Number of A&E visits
Total 5 1 6
Mean 0.20 0.04 0.13
Maximum 2 1 2
Proportion with community nurse contacts
Number 4 5 9
Percentage 16.0% 21.7% 18.8%
Number of community nurse contacts
Total 8 13 21
Mean 0.32 0.57 0.44
Maximum 3 4 4
Mortality rate
Number 1 1 2
Percentage 4.0% 4.3% 4.2%
Table 8 Required per arm sample size at P = 0.05 and 0.9
power
Relative
reduction
Absolute reduction
in number of admissions
per 100 discharges
Sample size
per arm
10% 3 4,240
15% 5 1,517
20% 7 768
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with high volume referral rates in one community would
simplify the research process. The study was conducted
within an existing clinical service, thus bringing in-
creased external validity through its pragmatic design
[24] and the ability to directly inform one region’s
commissioning choices with regard to Telehealth. How-
ever, the process of undertaking this study reinforces
findings from larger-scale studies (e.g., Hendy et al. [25])
regarding the difficulty of evaluating novel, complex in-
terventions such as Telehealth, especially when trying to
assess the utility of the intervention within a clinical ser-
vice alongside undertaking rigorous research.
The study was dependent upon one small clinical team
working against a backdrop of NHS restructuring. Even
though initial difficulties with obtaining staff ‘buy in’
were identified and appeared to be resolved during the
feasibility study, incremental demands created by the re-
search combined with the loss of a key champion for the
trial amongst the front line staff had a deleterious effect
over time. Further staff attrition resulted in an eventual
total loss of 60% of staff capacity within the frontline
clinical team. Thus, the main challenge of involving
frontline clinicians in the research and in data collection
was that, understandably, clinical priorities always came
first, and when resources were stretched there was little
room for the rigorous research processes which were re-
quired for the pilot trial. PCT budgetary restrictions pre-
vented return of the COPD team to its initial capacity.
The combined effect of reduced staff capacity and some
non-compliance with trial procedures (both staff and
participants) resulted in incomplete data collection and
slow recruitment to the trial. This also shows that GCP
training of clinical staff is not enough to ensure adherence
to trial procedures, thus research processes and data col-
lection need to be rigorously monitored throughout the
trial.
Despite the successful introduction of a Research
Nurse in month 10 to consent participants and collect
trial data, organisational changes within the PCT would
not have allowed continuation of the pilot trial to a full
RCT even if the limitations of the methodology were re-
solved. One example of an organisational change which
impacted the project was the national reorganisation of
the NHS, meaning that PCTs were disbanded in March
2013 and replaced by Clinical Commissioning Groups.
The consequences of both care pathways being rela-
tively new within what was a recently introduced service
cannot be underestimated. Fidelity to the pathways was
difficult to achieve at the outset and was readily compro-
mised. The waiting list for admission to the discharge
service, which began to build in month 4 of the pilot
trial due to the unanticipated 60% reduction in staff cap-
acity, is a clear example of how the care pathways were
changed due to service imperatives which were out of
the control of the research team.
There were issues regarding clinician commitment to
Telehealth and the work-based support they needed to
deliver this new intervention efficiently and appropri-
ately. The importance of training and on-going support
to deliver Telehealth is now recognised [14], but was not
available to the clinicians who participated in this study
with the consequence that adherence easily eroded and
Table 9 St George’s Respiratory Questionnaire (SGRQ) analysis for participants with valid baseline and 8-week SGRQ
scores
Time point Metric Standard (n = 9) Telehealth (n = 12)
Mean (SD) 65.34 (13.68)* 69.63 (16.58)
Baseline (n = 21) Median (IQR) 67.24 (52.97–77.73) 73.32 (55.16–83.85)
Min – Max (Range) 44.77–82.25 (37.48) 35.88–88.09 (52.21)
Mean (SD) 59.18 (13.21) 67.47 (15.70)
8-week (n = 21) Median (IQR) 62.14 (44.52–67.98) 69.99 (55.82–76.83)
Min – Max (Range) 42.71–81.66 (38.95) 37.18–87.88 (50.70)
*The SGRQ is scored from 0 (best possible health status) to 100 (worst possible health status).
Table 10 NHS cost and QALYs over 6 months
Item Standard
mean (n = 25)
Telehealth
mean (n = 28)
Mean
difference
Total costs £580 £1,749.8 £1,169.8
Quality adjusted life
years gained
0.20 0.217 0.017
Incremental
cost-effectiveness
ratio
£68,811 per QALY
Table 11 Community care costs and QALYs over 6 months
Item Standard
mean
(n = 25)
Telehealth
mean
(n = 28)
Mean
difference
Total costs £348.3 £383 £34.7
Quality adjusted
life years gained
0.20 0.217 0.017
Incremental
cost-effectiveness
ratio
£2,041 per QALY
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confidence waned. Problems with device connectivity for
some of the participants randomised to receive Telehealth
despite application of the study’s inclusion/exclusion cri-
teria reinforced the lack of clinician confidence.
Feedback from the feasibility study indicated that
those receiving the clinician-delivered ‘standard service’
valued this service and benefitted from it, and that both
groups expressed a preference for personalised face-to-
face service. The question this poses is whether those re-
ceiving Telehealth were disadvantaged in this instance
compared with those in receipt of a specialist face-to-
face service, which was highly tailored to patient need
but unlikely to be sustainable in the longer term. This
preference for face-to-face care may be more influential
than the perceived reassurance of daily monitoring pro-
vided through using Telehealth. Additionally, questions
were raised by the study regarding which patients might
gain most benefit from Telehealth. Study participants
were recruited at the point of hospital discharge and it
became evident that receptiveness to using Telehealth
could be severely compromised by their illness. It is pos-
sible that asking a patient to use a piece of technology at
this point, even one which is simple to use, could be a
daunting commitment to take on in addition to recover-
ing from their exacerbation. There are unanswered ques-
tions regarding when in the overall care pathway from
acute to primary care can Telehealth technology be most
effective and for how long, taking into account exacerba-
tion severity. There are also questions around the repre-
sentativeness of the sample, and when in the COPD
disease pathway deployment of Telehealth would be of
most benefit. Forty percent of patients referred to the
COPD service failed to qualify for the trial on one or
more of the eligibility criteria, indicating that trial partic-
ipants may not have been fully representative of the
COPD population as a whole and that our trial design
may not have been as ‘pragmatic’ as had been intended.
The definition of between one and three previous hos-
pital admissions, which formed a key component of the
eligibility criteria, was based on the local definition of early
stage COPD. However, it could be argued that a person
with three admissions in the previous 12 months may
have more advanced disease compared to someone with
one or no admissions. To summarise, commissioners and
clinicians require greater guidance for deployment.
By definition, complex interventions are difficult to de-
fine, standardise, and measure, and enthusiasm to
undertake research can underestimate this. The results
obtained from this study question the viability of involv-
ing front line clinical staff in data collection for robust
research evaluation. Whilst it is true that clinicians do
not need to be involved in data collection, the observa-
tions of Bird et al. [26] provide further support regarding
the importance of context and culture when conducting
trials, yet this is not evidenced through on-going com-
missioning of trials of complex interventions.
Questions remain regarding how to most appropriately
conduct local evaluations to inform commissioning deci-
sions. Leykum et al. [27] suggest integration of participa-
tory action research and randomised controlled trial
methods to ensure that a complex intervention is ad-
equately embedded within the setting. Arguably, this did
occur within this study through the extensive involve-
ment of commissioners and clinicians in study set up,
design, and progress, and through regular meetings dur-
ing the entire programme. As demonstrated by Hendy
et al. [25], the drive to demonstrate population-based
benefit through evaluation of complex interventions
does not necessarily equate with the demands of imple-
menting a complex intervention in situ.
Conclusions
We were able to complete an informative pilot RCT,
despite service reconfiguration and slow recruitment
rates. However, ultimately, these factors precluded pro-
gression to a full RCT in this setting. On the basis of
our experience in conducting this pilot study, we are
able to recommend that a definitive trial should be
multi-centre and aim to include 1,517 participants in
each arm. Consent, randomisation, and data collection
(in accordance with the protocol) should be supported
by dedicated research staff rather than by clinicians.
However, the study also raises a dilemma – there are in-
dications that patients prefer face-to-face contact even
when offered daily but remote interaction through Tele-
health, yet this model of care delivery may not be sus-
tainable in the current climate.
Endnote
aEarly stage COPD was defined as “Between one and
three previous admissions (including the current admis-
sion) in the previous 12 months from the current date of
discharge where COPD is the primary or secondary doc-
umented reason for hospitalisation”.
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